Abstract
Objectives
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-recognised condition that continues to be a therapeutic challenge. It can have devastating effects on patients’ quality of life. The literature recommends a myriad of management strategies. This case series demonstrates a combination of resection procedures, local reconstruction options and their impact on quality of life.
Patients and methods
This case series consisted of three patients with BRONJ following the use of bisphosphonates (BPs); for metastatic and metabolic bone diseases, none responded to conservative treatment. All patients were surgically managed by a standardised protocol combining bone resection and local reconstructive measures.
Results
We evaluated surgery-related change in quality of life using the “University of Washington Quality of Life Questionnaire”. At 3 months, all patients were pain free but were only able to manage soft foods and one persisted in using a straw for fluids. In all cases, quality of life scores showed an overall improvement or remained unchanged. There was no evidence of BRONJ recurrence.
Conclusion
Quality of life is an important consideration in the management of BRONJ patients. Optimal surgical resection and reconstruction may be an ideal treatment plan, but in medically compromised patients, this may not be possible. Consideration should be given to modified strategies with a potentially lower morbidity, yet still aiming to improve patients’ quality of life.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carter G, Goss AN, Doecke C (2005) Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 182(8):413–415
Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action in clinical practise. Mayo Clin Proc 83(9):1032–1045
Greenberg MS (2004) Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98(3):259–260
Marx RE, Stern DS (2002) Biopsy principles and techniques. In: Marx RE, Stern DS (eds) Oral and maxillofacial pathology: a rationale for diagnosis and treatment. Quintessence, Chicago, pp 36–38
Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced necrosis of the jaw: a growing epidemic. J Oral Maxillofacial Surg 61(9):1115–1118
Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102(4):433–441
American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the Jaws (2006) approved by the Board of Trustees September 25
American Dental Association Council on Scientific Affairs (2006) Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137(8):1144–1150
Bagan J, Blade J, Cozar JM, Constela M, Garcia Sanz R, Gómez-Veiga F et al (2007) Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 12:E336–E340
Ruggiero SL, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM et al (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2(1):7–14
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mahrotra B (2009) American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67(1):2–12
Khan AA, Sandor GKB, Dore E, Morisson AD, Alsahli M, Amin F et al (2008) Canadian consensus practise guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35(7):1391–1397
McLeod NM, Patel V, Kusanale A, Rogers SN, Brennan PA (2011) Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg 49(5):335–342
Van den Wygaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20(2):331–336
Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S et al (2009) Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management and treatment outcomes of 26 patients. J Oral Maxillofac Surg 67(9):1904–1913
Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N (2009) Bisphosphonate related osteonecrosis of the jaws: a single-centre study of 101 patients. J Oral Maxillofac Surg 67(4):850–855
Bedogni A, Saia G, Bettini G, Tronchet A, Totola A, Bedogni G, Ferronato G, Nocini PF, Blandamura S (2011) Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol 47(5):420–424
Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, Hemprich A (2011) The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111(2):153–163
Conflict of interest
No conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sadiq, Z., Sammut, S. & Lopes, V. Non-complex reconstructive techniques in the management of BRONJ: a case series of patient-related outcomes. Oral Maxillofac Surg 18, 223–227 (2014). https://doi.org/10.1007/s10006-013-0440-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10006-013-0440-3